Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Phase IV, single center, 2 arms randomized controlled, open label study. Study will be
conducted over a period of 42 days to determine the safety, tolerability, pharmacokinetics
and efficacy of ARCO.